Compare RAVE & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAVE | CTSO |
|---|---|---|
| Founded | 1958 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.1M | 45.7M |
| IPO Year | 1995 | 2008 |
| Metric | RAVE | CTSO |
|---|---|---|
| Price | $2.65 | $0.63 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 21.1K | ★ 69.0K |
| Earning Date | 05-07-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.76 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | $15,120,000.00 | ★ $22,503,908.00 |
| Revenue This Year | N/A | $7.29 |
| Revenue Next Year | N/A | $8.91 |
| P/E Ratio | $29.00 | ★ N/A |
| Revenue Growth | N/A | ★ 48.53 |
| 52 Week Low | $2.01 | $0.60 |
| 52 Week High | $3.75 | $1.39 |
| Indicator | RAVE | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 38.56 | 36.55 |
| Support Level | $2.34 | $0.62 |
| Resistance Level | $3.21 | $0.74 |
| Average True Range (ATR) | 0.13 | 0.06 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 48.65 | 10.23 |
Rave Restaurant Group Inc operates and franchises pizza buffet, delivery/carry-out, express restaurants, and ghost kitchens. It operates restaurants under the brand name, Pizza Inn, and Pie Five Pizza Company. It has three operating segments. The Pizza Inn Franchising and Pie Five Franchising segments establish franchisees, licensees, and territorial rights. The corporate administration and other segments. The Pizza Inn Franchising segment accounts for the majority of the company's revenue. Geographically, it generates the majority of the revenue from the United States.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.